

Are you dealing with crusty, itchy, red eyelids?

xdemvy[®]
(lotilaner ophthalmic solution) 0.25%

If so, it's time to speak to your eye doctor.

Demodex blepharitis—also known as DB—is an eyelid disease caused by an infestation of *Demodex* mites, which are a common mite found on humans.^{1,2} **It's estimated that approximately 25 million eye care patients in the US are affected by DB.**^{3,4}



Prepare to discuss your symptoms.

Bring this completed checklist to your next eye doctor appointment.

Responses are not a diagnosis.



→ **Over the past month, which signs and symptoms have you experienced?**^{1-3,5}
(Check all that apply.)

- | | |
|---|--|
| ☐ Eyelid redness | ☐ Missing or misdirected eyelashes |
| ☐ Crusties (collarettes) on eyelashes | ☐ Eyelid itching |
| ☐ Eyelid irritation | ☐ Eyelid swelling |

→ **How are you currently managing your symptoms?**
(Check all that apply.)

- | | |
|---|---------------------------------------|
| ☐ Eyelid cleanser | ☐ Warm compresses |
| ☐ Eyelid wipes | ☐ Baby shampoo |
| ☐ Eyelid foams | ☐ Other _____ |
| ☐ In-office eyelid treatments | |

→ **How would you describe your current symptom management plan?**
(Check all that apply.)

- | | |
|--|--|
| ☐ Cumbersome | ☐ Working OK but could be better |
| ☐ Difficult to adhere to | ☐ Working OK |
| ☐ Not managing my symptoms | ☐ Other _____ |

→ **Have your symptoms made it harder to do any of these daily activities?**
(Check all that apply.)

- | | |
|---|---|
| ☐ School/office work | ☐ Difficulty driving at night |
| ☐ Family or social gatherings | ☐ Daily hygiene routine |
| ☐ Taking vacations or travel | ☐ Other _____ |
| ☐ Wearing makeup | |

→ **When do your symptoms occur most often?**
(Select the option that best fits you.)

- | | |
|--|---|
| ☐ First thing in the morning | ☐ At night/when trying to sleep |
| ☐ During the day | |

→ **How often do you visit an eye doctor?**
(Select one.)

- | | |
|---|---|
| ☐ Multiple times a year | ☐ Only when I am having issues with my eyes |
| ☐ Once a year | |
| ☐ I have never seen an eye doctor | |

Indications and Usage

XDEMVY (lotilaner ophthalmic solution) 0.25% is indicated for the treatment of *Demodex* blepharitis.

Important Safety Information

Most common side effects: The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

Please see additional Important Safety Information on next page and full [Prescribing Information](#) attached.

Ready to break up your mite party? XDEMVMY® can help.

xdemvy[®]
(lotilaner ophthalmic
solution) 0.25%

Your eye doctor can prescribe XDEMVMY, the **only FDA-approved eye drop treatment** that targets and kills the *Demodex* mites that cause DB.⁶

→ **One drop per eye, twice a day, approximately 12 hours apart, in just 6 weeks**

In 2 combined studies, 50% of patients had a reduction of crusties (collarettes) and 60% of patients had their *Demodex* mites completely wiped out^{7*}

→ **Designed for comfort**

~90% of patients in 2 combined studies reported XDEMVMY eye drops as neutral to very comfortable to use^{7†}

→ **Stay on top of your treatment**

It's important to use XDEMVMY for the full 6 weeks

→ **Reduce eyelid redness**

Patients using XDEMVMY for DB may see eyelid redness gone in just 6 weeks⁶

→ **Maintain eyelid health**

Over time, mites may come back, so it's important to see your eye doctor regularly. If signs and symptoms such as eyelid redness, itching, or crusties (collarettes) return, make an appointment to visit your eye doctor right away so they can check for DB^{1,3,5}

→ **Tarsus Connect**

Tarsus is committed to making XDEMVMY affordable and accessible.

Insurance coverage of XDEMVMY continues to expand, reaching an average of over 85% of insured patients across Commercial, Medicare Part D, and Medicaid. The majority of patients pay \$30 or less[‡]

- Please ask your pharmacist how you can save on XDEMVMY
- The pharmacy may require personal information like your social security number to evaluate your eligibility for financial assistance




BEFORE



AFTER

Real patient with DB used XDEMVMY twice daily, in each eye, for 6 weeks. Results may vary.



If you think you might have DB, scan the QR code to find an eye doctor near you!

* XDEMVMY for *Demodex* blepharitis was evaluated in 2 pivotal trials of 833 patients (415 received XDEMVMY).^{6,8,9}

Trial 1: When taken twice daily in each eye for 6 weeks, XDEMVMY reduced collarettes to 2 or less for the upper eyelid in 44% of patients (n=209) at Day 43; XDEMVMY eradicated mites (mite density of 0 mites/lash) in 68% of patients (n=212) at Day 43.

Trial 2: When taken twice daily in each eye for 6 weeks, XDEMVMY reduced collarettes to 2 or less for the upper eyelid in 55% of patients (n=193) at Day 43; XDEMVMY eradicated mites (mite density of 0 mites/lash) in 50% of patients (n=203) at Day 43.

† All visits averaged.⁷

‡ With payer coverage and available assistance options, and based on eligibility requirements; see XDEMVMY Savings and Access [Terms and Conditions](#).

Important Safety Information (Cont'd)

Handling the Container: Avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

When to Seek Physician Advice: Immediately seek a physician's advice concerning the continued use of XDEMVMY if you develop an intercurrent ocular condition (e.g., trauma or infection), have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions.

Use with Contact Lenses: XDEMVMY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVMY and may be reinserted 15 minutes following its administration.

To report SUSPECTED ADVERSE REACTIONS, contact Tarsus Pharmaceuticals at 1-888-421-4002 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information attached.

By prescription only.

References: 1. Fromstein SR, Harthan JS, Patel J, Opitz DL. *Demodex* blepharitis: clinical perspectives. *Clin Optim (Auckl)*. 2018;10:57-63. 2. Rhee MK, Yeu E, Barnett M, et al. *Demodex* blepharitis: a comprehensive review of the disease, current management, and emerging therapies. *Eye Contact Lens*. 2023;49(8):311-318. 3. Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of *Demodex* blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign. *Clin Ophthalmol*. 2022;16:1153-1164. 4. O'Dell L, Dierker DS, Devries DK, et al. Psychosocial impact of *Demodex* blepharitis. *Clin Ophthalmol*. 2022;16:2979-2987. 5. Sędzikowska A, Osęka M, Grytner-Zięcina B. Ocular symptoms reported by patients infested with *Demodex* mites. *Acta Parasitol*. 2016;61(4):808-814. 6. XDEMVMY. Prescribing Information. Tarsus Pharmaceuticals Inc; 2023. 7. Yeu E, Paaup JD, Vollmer P, et al. Safety and efficacy of lotilaner ophthalmic solution (0.25%) in treating *Demodex* blepharitis: pooled analysis of two pivotal trials. *Ophthalmol Ther*. 2025;14(3):555-571. 8. Gaddie IB, Donnenfeld ED, Karpecki P, et al. Lotilaner ophthalmic solution 0.25% for *Demodex* blepharitis: randomized, vehicle-controlled, multicenter, phase 3 trial (Saturn-2). *Ophthalmology*. 2023;130(10):1015-1023. 9. Yeu E, Wirtz DL, Karpecki P, Baba SN, Holdbrook M; Saturn I Study Group. Lotilaner ophthalmic solution, 0.25%, for the treatment of *Demodex* blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1). *Cornea*. 2023;42(4):435-443.



©2026 Tarsus Pharmaceuticals, Inc. All rights reserved.

XDEMVMY, TARSUS, certain other trademarks, and any associated logo(s) herein are trademarks owned exclusively by Tarsus Pharmaceuticals, Inc. US-2600002/2/26